Tragic Loss: Centre Enforces Urgent Drug Testing After Toxic Cough Syrup Kills 14 Innocent Children
New Delhi: In response to a devastating incident in Madhya Pradesh that resulted in the deaths of over a dozen children, the Centre has mandated stricter enforcement of drug testing regulations across India. On October 7, the Drugs Controller General of India (DCGI) issued a directive aimed at all state and Union territory drug controllers, calling for rigorous testing of both raw materials and finished pharmaceutical products.
The urgent move follows the tragic loss of at least 14 children in Chhindwara who suffered from renal failure after allegedly consuming contaminated cough syrup. Investigations revealed alarming lapses in testing protocols at manufacturing sites, highlighting that many drugmakers had failed to conduct mandatory testing of every batch of excipients and active pharmaceutical ingredients, in clear violation of the Drugs Rules of 1945.
This systemic failure allowed substandard drugs to infiltrate the market, posing a serious threat to public health. To address these issues, the DCGI has made it mandatory for all licensed manufacturers to establish either an in-house laboratory or utilize an approved external facility to test every batch of raw materials and final products. Alongside this, comprehensive records of all tests must be maintained as dictated by existing regulations.
Importantly, the directive underscores the need for a robust vendor qualification system to ensure that raw materials are sourced exclusively from vetted and reliable suppliers. This proactive measure aims to prevent contaminated or substandard ingredients from entering the manufacturing pipeline. The grave nature of the Chhindwara incident, where a government doctor was arrested for allegedly prescribing a cough syrup containing dangerously high levels of diethylene glycol (DEG)—a toxic industrial solvent-heightens the urgency of these new measures. Reports indicate that the DEG concentration in the cough syrup was approximately 48.6%, significantly exceeding permissible limits, and is known to cause acute kidney failure in children.
The specific syrup, known as Coldrif, was produced by Sresan Pharmaceuticals, a company based in Tamil Nadu. Investigations into their manufacturing practices unearthed numerous violations, including unclean facilities, defective equipment, and the use of non-pharmaceutical grade chemicals. Alarmingly, the company’s license had remained unchecked for over a decade.
By tightening quality control measures from the source, the government aims to restore faith in India’s pharmaceutical sector, which plays a key role as a global supplier of generic medicines. This comprehensive approach, focusing on enhancing testing protocols and vendor reliability, seeks to safeguard public health and prevent future tragedies.
As the country grapples with these critical issues in pharmaceutical safety, the urgency of stringent regulations has never been clearer. The DCGI’s directive marks a pivotal moment in fortifying the integrity of India’s drug manufacturing landscape, establishing a precedent for accountability and public health prioritization in the pharmaceutical industry. The aim is to ensure that such heart-wrenching incidents do not recur, preserving the health and well-being of the nation’s most vulnerable populations.
Original Source: https://www.livemint.com/news/india/dcgi-directs-states-to-enforce-strict-drug-testing-after-mp-childrens-deaths-due-to-contaminated-cough-syrup-11759941378421.html
Category :
Tags:
Publish Date: 2025-10-08 23:38:00
